Meteda

Digital Health Software for Diabetes and Chronic Disease Managementmeteda.it

Meteda, an IQVIA business founded in 2002, develops Class IIa certified digital health software, AI screening, telemedicine, and nutrition hardware for diabetology centers, hospitals, and chronic disease management providers across Italy and Portugal.

Company typePrivate
Founded2002
HeadquartersRoma, Italy
Headcount11–50
GTM typeB2B
OfferingSoftware

What Meteda does

Meteda S.r.l., operating as an IQVIA business since 2002, is an Italian digital health company that develops and distributes certified Class IIa medical device software and hardware for diabetes, chronic disease, and clinical nutrition management. Its core platform, MetaClinic®, is a Class IIa certified electronic medical record used by over 90% of Italian diabetology centers to manage patient follow-up, clinical documentation, complication assessments, and care pathways across multi-center deployments with unified databases. The portfolio is extended by DAIRET® (an AI deep-learning algorithm for diabetic retinopathy screening acquired via the 2022 Retmarker SA acquisition and validated on 500,000+ patients), a telemedicine suite (SmartVisit®, SmartLink®, GliConnect®) certified for Italy's Ministerial Decree 30/09/2022 telemedicine infrastructure, the MetaDieta® ecosystem (MetaDieta Studio® cloud software, MetaDieta BIA® bioimpedance hardware, MetaDieta Academy training, and MetaCare support), and Glucomagic® for glucose self-monitoring device data. All products are interoperable with Italy's Fascicolo Sanitario Elettronico (FSE 2.0), Regional Telemedicine Infrastructures, and Local Health Authorities.

The company monetizes primarily through enterprise license sales (sold as annual subscriptions to healthcare institutions), hardware device sales (MetaDieta BIA®, telemedicine kits), and recurring support and training services (MetaCare, MetaDieta Academy). Go-to-market is sales-led, with a direct sales team ([email protected]) and field engagement at events like the AMD National Congress targeting diabetology centers, hospitals, and chronic disease management facilities, supplemented by referral networks through IQVIA and the AMD scientific society. Customers are concentrated in Italy, with secondary operations in Portugal (via Retmarker SA) and international expansion signaled through participation in EU-funded research consortia (DigiCare4You, MindLink, CRANE, CORRAL). Multiple ISO certifications (9001, 13485, 27001 with 27017/27018) and UNI/PdR 125:2022 gender equality certification underpin institutional procurement eligibility.

Meteda firmographics

Firmographics

Name: Meteda
Legal name: METEDA S.r.l.
Website: https://meteda.it
Company type: Private
Founded year: 2002
Operating status: Operating
Headcount range: 11–50 employees
Short description: Meteda, an IQVIA business founded in 2002, develops Class IIa certified digital health software, AI screening, telemedicine, and nutrition hardware for diabetology centers, hospitals, and chronic disease management providers across Italy and Portugal.
Ownership category
akta.pro rank

Meteda industry classification

Industry

Product category: Digital Health Software for Diabetes and Chronic Disease Management
NAICS: Software Publishers (5132), Surgical Appliance and Supplies Manufacturing (339113), Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
SIC: Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841), Services-Misc Health & Allied Services, Nec (8090)
akta.pro primary industry: Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management) (HLALAFAL)
akta.pro secondary industries: Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Medical Device Connectivity & Interoperability Middleware (MDI, EHR/HL7/FHIR Integration) (HLACAPAJ), Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD), Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)

Keywords

Digital health software
Diabetes management
Medical device certification
Telemedicine platforms
Clinical decision support

Where Meteda is headquartered

Location

Headquarters

HQ city: Roma
HQ country: Italy
HQ region: Europe

Offices4 records

Markets served

Meteda business model

Business model

GTM type: B2B
Offering type: Software
Cost components: Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

Medical Software Licenses: Sale of certified medical device software (Class IIa) to healthcare institutions including diabetology centers, hospitals, and chronic disease management facilities. Sold as licensed software with ongoing support and updates.
Hardware Devices: Sale of certified medical hardware including MetaDieta BIA® portable bioimpedance analyzers, glucose monitoring integration devices, and telemedicine equipment.
Support and Training Services: MetaCare support services and MetaDieta Academy training programs provided to healthcare professionals and institutions using Meteda platforms.

Pricing tiers

Model	Billing	Price
Subscription	Annual	Enterprise healthcare institution licensing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Meteda product offering

Product offering

Core offering

Meteda develops and distributes certified Class IIa medical device software and hardware for diabetes and chronic disease management. Its core product, MetaClinic®, is a digital electronic medical record used in over 90% of Italian diabetology centers, supported by telemedicine devices (SmartVisit®, SmartLink®, GliConnect®), a nutrition ecosystem (MetaDieta®), and AI-powered screening tools (DAIRET®). Solutions are sold as annual software subscriptions and hardware to healthcare institutions, hospitals, and chronic disease management facilities.

Product overview

Meteda develops a comprehensive digital health ecosystem comprising multiple integrated products: MetaClinic® (Class IIa certified electronic medical record for diabetology and chronic diseases, deployed in over 90% of Italian diabetes centers), telemedicine modules (SmartVisit® for televisits, SmartLink® for secure messaging, GliConnect® for glucose telemonitoring), MetaDieta® ecosystem (MetaDieta Studio® cloud platform, MetaDieta BIA® bioimpedance device, MetaCare support services, MetaDieta Academy training), Glucomagic® glucose monitoring software, and AI-powered DAIRET® for diabetic retinopathy screening. The company operates as an IQVIA business focused on chronic disease management solutions.

Differentiator

Problem solved

Functional benefit

Brands

MetaClinic: Class IIa certified electronic medical record for diabetology and chronic disease management, used in over 90% of Italian diabetology centers
MetaDieta
SmartVisit
SmartLink
GliConnect
DAIRET
Retmarker

Products and services

MetaClinic®

Quantifiable outcome

Used in over 90% of Italian diabetology centers
+3 more outcomes

Companies that use Meteda

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Meteda technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability5 records

Feature6 records

Meteda partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core, major and strategic.

Retmarker SAcoreStrategic or Co-development Partner · 19 January 2022Meteda acquired Portuguese AI company Retmarker SA in January 2022 to enhance diabetic retinopathy screening solutions. Retmarker developed the AI algorithm Screening DR, used on over 500,000 patients and validated in international scientific publications. The technology is now integrated as DAIRET® in MetaClinic®.
Associazione Medici Diabetologi (AMD)majorStrategic or Co-development PartnerAMD is the Italian Association of Diabetologists. MetaClinic® is recognized by AMD as a proven tool supporting nationwide diabetes care and management. The collaboration enables publication of AMD Annals, a key survey on Italian diabetology based on data collected through MetaClinic®.
European Research Consortium PartnersstrategicStrategic or Co-development PartnerMeteda participates in European research projects including DigiCare4You (2021-2026), MindLink, CRANE (Pre-Commercial Procurement), and Corral, collaborating with universities, research centers, and international industrial partners to develop and test new models of care based on data, AI, interoperability, and personalized medicine.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Meteda competitors and assessment

Company assessment

Broad incumbents

Dexcom: Global continuous glucose monitoring leader whose Clarity software overlaps with Glucomagic®; broad incumbent adjacent to Meteda's glucose telemonitoring module GliConnect®.
Dedalus Group: Major European healthcare IT vendor offering hospital EHRs and diagnostic modules across Italy; broad incumbent competing with MetaClinic® at the hospital-procurement level.
Medtronic Diabetes: Global incumbent in insulin pumps, CGM systems, and diabetes decision-support software; competes with Meteda's diabetes management and telemonitoring stack.

Direct peers

mySugr (Roche): Diabetes management app and platform owned by Roche; directly competes with MetaClinic® in digital diabetes diaries, glucose tracking, and clinician-facing tools.
Glooko: Device-agnostic diabetes data management platform aggregating data from glucometers, insulin pumps, and CGMs; comparable to Glucomagic® and MetaClinic® in data aggregation across diabetes devices.
DarioHealth: Public digital therapeutics company focused on diabetes and chronic-condition management; competes with Meteda in chronic care platforms and AI-driven patient coaching.
Vivify Health: Remote patient monitoring and chronic care management platform for health plans and providers; comparable to GliConnect®-style RPM combined with EMR integration.

Emerging players

Luscii: European platform for remote patient monitoring and virtual care, including chronic-condition programs; comparable to SmartVisit®, SmartLink®, and GliConnect® telemedicine devices.
Tidepool: Nonprofit diabetes data platform with strong clinician and patient tooling for diabetes device data; comparable as an interoperable, multi-condition diabetes data ecosystem.
Voluntis (AptarGroup): Digital therapeutics company historically focused on insulin titration in diabetes; highly comparable to MetaClinic's AI-driven decision support and predictive complication features.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Meteda compliance and trust

Trust signal

Compliance7 records

Meteda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Meteda leadership team

Management profile

Number of profiles

Profiles1 record

Meteda subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Meteda funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Meteda M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meteda

What does Meteda do?

Is Meteda a public or private company?

Meteda is a private company. It is classified as corporate owned and is currently operating.

When was Meteda founded?

Meteda was founded in 2002. It employs 11 to 50 people.

Where is Meteda based?

Meteda is headquartered in Roma, Italy, in the Europe region.

How does Meteda make money?

Three revenue lines are on record. Medical Software Licenses are the primary driver. The others are hardware Devices and support and Training Services.

Who are Meteda's main competitors?

Broad incumbents on record are Dexcom, Dedalus Group and Medtronic Diabetes. Direct peers are mySugr (Roche), Glooko, DarioHealth and Vivify Health. Emerging players are Luscii, Tidepool and Voluntis (AptarGroup).

Does Meteda have an API?

No public API is recorded for Meteda.

What industry is Meteda in?

Meteda's product category is Digital Health Software for Diabetes and Chronic Disease Management. Its primary akta.pro industry code is HLALAFAL, Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 5132 and its SIC code is 7372.